{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T05:46:46Z","timestamp":1740808006858,"version":"3.38.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":915,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1124\/dmd.122.000836","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T15:50:57Z","timestamp":1653321057000},"page":"980-988","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sinusoidal Uptake Determines the Hepatic Clearance of Pevonedistat (TAK-924) as Explained by Extended Clearance Model"],"prefix":"10.1016","volume":"50","author":[{"given":"Philip","family":"Sandoval","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bei-Ching","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Yoneyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeepraj","family":"Pusalkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Yucha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swapan K","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paresh P.","family":"Chothe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.122.000836_bib1","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3390\/ijms19030855","article-title":"Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions","volume":"19","author":"Alam","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1124\/dmd.122.000836_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10637-016-0348-5","article-title":"A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924\/MLN4924) in patients with metastatic melanoma","volume":"34","author":"Bhatia","year":"2016","journal-title":"Invest New Drugs"},{"key":"10.1124\/dmd.122.000836_bib3","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/jpet.119.257600","article-title":"Quantitative Contribution of Six Major Transporters to the Hepatic Uptake of Drugs: \u201cSLC-Phenotyping\u201d Using Primary Human Hepatocytes","volume":"370","author":"Bi","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.122.000836_bib4","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1021\/acs.molpharmaceut.7b01108","article-title":"Role of Hepatic Organic Anion Transporter 2 in the Pharmacokinetics of R- and S-Warfarin: In Vitro Studies and Mechanistic Evaluation","volume":"15","author":"Bi","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.122.000836_bib5","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1124\/jpet.117.245951","article-title":"Organic Anion Transporter 2 Mediates Hepatic Uptake of Tolbutamide, a CYP2C9 Probe Drug","volume":"364","author":"Bi","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.122.000836_bib6","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1124\/dmd.114.057968","article-title":"Differential effects of Rifampin and Ketoconazole on the blood and liver concentration of atorvastatin in wild-type and Cyp3a and Oatp1a\/b knockout mice","volume":"42","author":"Chang","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000836_bib7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1124\/dmd.120.000057","article-title":"Function and Expression of Bile Salt Export Pump in Suspension Human Hepatocytes","volume":"49","author":"Chothe","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000836_bib8","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1021\/acs.molpharmaceut.8b00654","article-title":"Assessment of Transporter-Mediated and Passive Hepatic Uptake Clearance Using Rifamycin-SV as a Pan-Inhibitor of Active Uptake","volume":"15","author":"Chothe","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.122.000836_bib9","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/bcp.13915","article-title":"Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours","volume":"85","author":"Faessel","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000836_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/1872312810666160411144358","article-title":"Rate-Determining and Rate-Limiting Steps in the Clearance and Excretion of a Potent and Selective p21-Activated Kinase Inhibitor: A Case Study of Rapid Hepatic Uptake and Slow Elimination in Rat","volume":"10","author":"Fan","year":"2016","journal-title":"Drug Metab Lett"},{"key":"10.1124\/dmd.122.000836_bib11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejps.2018.09.021","article-title":"Strategies to improve the prediction accuracy of hepatic intrinsic clearance of three antidiabetic drugs: Application of the extended clearance concept and consideration of the effect of albumin on CYP2C metabolism and OATP1B-mediated hepatic uptake","volume":"125","author":"Fujino","year":"2018","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.122.000836_bib12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/clpt.2013.74","article-title":"Emerging transporters of clinical importance: an update from the International Transporter Consortium","volume":"94","author":"Hillgren","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000836_bib13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.122.000836_bib14","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1124\/dmd.105.009175","article-title":"Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans","volume":"34","author":"Ishiguro","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000836_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2019.106590","article-title":"Targeted quantitative proteomic analysis of drug metabolizing enzymes and transporters by nano LC-MS\/MS in the sandwich cultured human hepatocyte model","volume":"98","author":"Khatri","year":"2019","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1124\/dmd.122.000836_bib16","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/jpet.118.252049","article-title":"Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs","volume":"367","author":"Kimoto","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.122.000836_bib17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1515\/dmdi-2015-0003","article-title":"Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins","volume":"30","author":"Kunze","year":"2015","journal-title":"Drug Metab Pers Ther"},{"key":"10.1124\/dmd.122.000836_bib18","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1080\/17425255.2021.1912012","article-title":"Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated clearance","volume":"17","author":"Liang","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.122.000836_bib19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10637-018-0610-0","article-title":"Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors","volume":"37","author":"Lockhart","year":"2019","journal-title":"Invest New Drugs"},{"key":"10.1124\/dmd.122.000836_bib20","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1124\/dmd.113.054528","article-title":"Functional ATP-binding cassette drug efflux transporters in isolated human and rat hepatocytes significantly affect assessment of drug disposition","volume":"42","author":"Lundquist","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000836_bib21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/clpt.2011.142","article-title":"Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study","volume":"90","author":"Maeda","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000836_bib22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1124\/dmd.117.077115","article-title":"The Phenomenon of Albumin-Mediated Hepatic Uptake of Organic Anion Transport Polypeptide Substrates: Prediction of the In Vivo Uptake Clearance from the In Vitro Uptake by Isolated Hepatocytes Using a Facilitated-Dissociation Model","volume":"46","author":"Miyauchi","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000836_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.07.025","article-title":"Hepatic clearance concepts and misconceptions: Why the well-stirred model is still used even though it is not physiologic reality?","volume":"169","author":"Pang","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.122.000836_bib24","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1124\/dmd.118.081307","article-title":"When Does the Rate-Determining Step in the Hepatic Clearance of a Drug Switch from Sinusoidal Uptake to All Hepatobiliary Clearances? Implications for Predicting Drug-Drug Interactions","volume":"46","author":"Patilea-Vrana","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000836_bib25","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1124\/dmd.117.078972","article-title":"Physiologically Based Pharmacokinetic Modeling of Bosentan Identifies the Saturable Hepatic Uptake As a Major Contributor to Its Nonlinear Pharmacokinetics","volume":"46","author":"Sato","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000836_bib26","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2133\/dmpk.DMPK-10-RV-094","article-title":"Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions","volume":"26","author":"Shitara","year":"2011","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.122.000836_bib27","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.tiv.2006.06.003","article-title":"Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements","volume":"20","author":"Sohlenius-Sternbeck","year":"2006","journal-title":"Toxicol In Vitro"},{"key":"10.1124\/dmd.122.000836_bib28","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood-2017-09-805895","article-title":"Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML","volume":"131","author":"Swords","year":"2018","journal-title":"Blood"},{"key":"10.1124\/dmd.122.000836_bib29","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1124\/jpet.114.215970","article-title":"Quantitative prediction of transporter- and enzyme-mediated clinical drug-drug interactions of organic anion-transporting polypeptide 1B1 substrates using a mechanistic net-effect model","volume":"351","author":"Varma","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.122.000836_bib30","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s11095-012-0956-5","article-title":"Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide","volume":"30","author":"Varma","year":"2013","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.122.000836_bib31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nrd2353","article-title":"Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery","volume":"7","author":"Wasan","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.122.000836_bib32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1124\/dmd.109.030254","article-title":"Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans","volume":"38","author":"Watanabe","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000836_bib33","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1007\/s11095-017-2168-5","article-title":"A Clinical Cassette Dosing Study for Evaluating the Contribution of Hepatic OATPs and CYP3A to Drug-Drug Interactions","volume":"34","author":"Yoshikado","year":"2017","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.122.000836_bib34","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1124\/dmd.119.086744","article-title":"Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule-Related Therapeutic Modalities","volume":"47","author":"Zhang","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000836_bib35","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s10637-020-01017-x","article-title":"Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors","volume":"39","author":"Zhou","year":"2021","journal-title":"Invest New Drugs"},{"issue":"S1","key":"10.1124\/dmd.122.000836_bib36","first-page":"1","article-title":"Hepatic Uptake as a Rate-determining Step in Clearance: A Physiologically-based Pharmacokintic Model for Pevonedistat to Explore Mechanisms of Lack of Clinically-observed Drug-Drug Interactions with CYP3A Inhibitors & Inducers. Poster number-030","volume":"10","author":"Zhou","year":"2021","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562400833X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562400833X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.122.000836","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:01:49Z","timestamp":1740765709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009095562400833X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S009095562400833X"],"URL":"https:\/\/doi.org\/10.1124\/dmd.122.000836","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sinusoidal Uptake Determines the Hepatic Clearance of Pevonedistat (TAK-924) as Explained by Extended Clearance Model","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.122.000836","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by The Author(s)","name":"copyright","label":"Copyright"}]}}